Request Demo
Last update 27 Feb 2026
Fibrin Sealant (Human) (Omrix)
Last update 27 Feb 2026
Overview
Basic Info
Drug Type Non-recombinant coagulation factor |
Synonyms Fibrin Sealant Patch, Crosseal, Evarrest + [1] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (21 Mar 2003), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 1216176
Sequence Code 9681008
Related
23
Clinical Trials associated with Fibrin Sealant (Human) (Omrix)NCT03255174
A Prospective Study Evaluating the Safety and Effectiveness of EVARREST® Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (Non-cardiac) Surgery in Pediatric Patients
NCT02553122
The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty During the Early Perioperative Period
NCT02457546
A Single-Blinded, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® Fibrin Sealant (Human) Compared to a Hydrogel Sealant as an Adjunct to Sutured Dural Repair
100 Clinical Results associated with Fibrin Sealant (Human) (Omrix)
Login to view more data
100 Translational Medicine associated with Fibrin Sealant (Human) (Omrix)
Login to view more data
100 Patents (Medical) associated with Fibrin Sealant (Human) (Omrix)
Login to view more data
58
Literatures (Medical) associated with Fibrin Sealant (Human) (Omrix)01 Nov 2024JOURNAL OF PEDIATRIC SURGERY
A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery
Article
Author: Balanescu, Laura ; Slavkovic, Andjelka ; Camprubí, Sandra ; Hanna, Kim ; James, Michael K. ; Jenovari, Zoltan ; Querolt, Montse ; Gajdobranski, Djordje ; Bozzo, Jordi ; Mikickovic, Maja ; Kamenov, Krasimir ; Vajda, Péter ; Camprubí, Sandra ; Irtan, Sabine ; Querolt, Montse ; Mondou, Elsa ; Mondou, Elsa ; Kalinova, Krasimira ; Sharif, Khalid ; Ninov, Borislav ; Simeonov, Simeon ; Sretenović, Aleksandar ; Wiener, Isodoro ; Hanna, Kim
BACKGROUND:
In this study, two fibrin sealant products, Fibrin Sealant Grifols (FS Grifols 80 mg/mL fibrinogen; 500 IU/mL thrombin) and Evicel (fibrinogen 55-85 mg/mL; thrombin 800-1200 IU/mL) were studied for efficacy in achieving hemostasis at a targeted bleeding site (TBS) on parenchymous or soft tissue in pediatric surgeries.
METHODS:
This phase 3, single-blind, active comparator, non-inferiority trial compared the number of patients achieving hemostasis at a TBS at four (T4 - primary endpoint), seven (T7) and 10 (T10) minutes after application, Safety and tolerability were assessed by recording adverse events during and after procedures. Eligible patients were <18 years old undergoing elective, open, non-cardiac thoracic, abdominal or pelvic surgeries. Preterm (<37 weeks gestation) and newborn (0-27 days) infants were eligible.
RESULTS:
At T4, 98.7% of FS Grifols group (n = 91) and 95.4% of the Evicel group (n = 87) achieved hemostasis. All patients with residual bleeding at T4 were undergoing soft tissue surgery. All patients achieved hemostasis by T7. At T10, all patients achieved hemostasis except one (FS Grifols (no observation recorded)). There were no incidents of persistent bleeding. For FS Grifols, 26.5% of patients had treatment-emergent adverse events (TEAEs) and 18.4% for Evicel. One TEAE (moderate procedural pain - FS Grifols group) was considered possibly related to study treatment. Three patients died for reasons unrelated to the study medications.
CONCLUSIONS:
FS Grifols was safe and effective at achieving hemostasis in pediatric patients having parenchymous or soft tissue surgeries. The efficacy of FS Grifols was non-inferior to Evicel.
LEVEL OF EVIDENCE:
I.
01 Sep 2024CHILDS NERVOUS SYSTEM
Correction to: Safety and effectiveness of Evicel® fibrin sealant as an adjunct to sutured dural repair in children undergoing cranial neurosurgery
Author: Ilie, Bogdan ; Josan, Vivek ; Sivakumar, Gnanamurthy ; Kandasamy, Jothy ; Aquilina, Kristian ; Pettorini, Benedetta ; Kocharian, Richard ; Magdum, Shailendra ; Barnett, Ellie
01 Sep 2024CHILDS NERVOUS SYSTEM
Safety and effectiveness of Evicel® fibrin sealant as an adjunct to sutured dural repair in children undergoing cranial neurosurgery
Article
Author: Ilie, Bogdan ; Josan, Vivek ; Sivakumar, Gnanamurthy ; Kandasamy, Jothy ; Aquilina, Kristian ; Kocharian, Richard ; Pettorini, Benedetta ; Magdum, Shailendra ; Barnett, Ellie
Abstract:
Purpose:
Cerebrospinal fluid (CSF) leakage is a challenging complication of intradural cranial surgery, and children are particularly at risk. The use of dural sealants confers protection in adults, but pediatric studies are scarce. We evaluated the safety and efficacy of Evicel® fibrin sealant as an adjunct to primary dural suturing in children undergoing cranial surgery.
Methods:
A multicenter trial prospectively enrolled pediatric subjects (< 18 years) undergoing cranial neurosurgery who, upon completion of primary sutured dural repair, experienced CSF leakage. As agreed by the EMA Evicel® Pediatric Investigation Plan, 40 subjects were intra-operatively randomized 2:1 to Evicel® or additional sutures (‘Sutures’). Data analysis was descriptive. The efficacy endpoint was treatment success rate, with success defined as intra-operative watertight closure after provocative Valsalva maneuver (primary endpoint). Safety endpoints were postoperative CSF leakage (incisional CSF leakage, pseudomeningocele or both) and surgical site complications (secondary endpoints).
Results:
Forty subjects (0.6–17 years) were randomized to Evicel® (N = 25) or Sutures (N = 15) (intention-to-treat). Intracranial tumor was the most common indication and procedures were mostly supratentorial craniotomies. Success rates were 92.0% for Evicel® and 33.3% for Sutures, with a 2.76 estimated ratio of success rates (Farrington-Manning 95% CI [1.53, 6.16]). Sensitivity analyses in per-protocol and safety sets showed similar results. Despite a higher rescue treatment rate, the frequencies of postoperative CSF leakage and wound complications were higher for Sutures than for Evicel®.
Conclusion:
This small-scale prospective study shows Evicel® treatment to be safe and effective as an adjunct to primary sutured dura mater closure in a pediatric population. Compared to additional sutures, Evicel® was associated with reduced postoperative CSF leakage and surgical site complications. (Trial registration: The trial was registered as NCT02309645 and EudraCT 2013-003558-26).
100 Deals associated with Fibrin Sealant (Human) (Omrix)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Blood Coagulation Disorders | European Union | 05 Oct 2008 | |
| Blood Coagulation Disorders | Iceland | 05 Oct 2008 | |
| Blood Coagulation Disorders | Liechtenstein | 05 Oct 2008 | |
| Blood Coagulation Disorders | Norway | 05 Oct 2008 | |
| Hemorrhage | United States | 21 Mar 2003 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Cerebrospinal Fluid Leak | Phase 3 | United Kingdom | 01 Oct 2014 | |
| Cardiovascular Diseases | Phase 3 | United States | 01 Jan 2014 | |
| Cardiovascular Diseases | Phase 3 | Japan | 01 Jan 2014 | |
| Cardiovascular Diseases | Phase 3 | Australia | 01 Jan 2014 | |
| Cardiovascular Diseases | Phase 3 | Belgium | 01 Jan 2014 | |
| Cardiovascular Diseases | Phase 3 | United Kingdom | 01 Jan 2014 | |
| Cerebral Hemorrhage | Phase 3 | United Kingdom | 20 Sep 2013 | |
| Peripheral Vascular Diseases | Phase 3 | United States | 01 Jun 2005 | |
| Peripheral Vascular Diseases | Phase 3 | United States | 01 Jun 2005 | |
| Peripheral Vascular Diseases | Phase 3 | United Kingdom | 01 Jun 2005 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 40 | vhfnbaiibe(fgumlywbtw) = fjhvstkson spvuslxmuh (otwzxqgaih ) | Positive | 10 May 2024 | |||
Sutures | vhfnbaiibe(fgumlywbtw) = kjhrkadlyb spvuslxmuh (otwzxqgaih ) | ||||||
Phase 3 | 40 | (EVARREST Sealant Matrix) | vszmyneanx(kcnfvfvwfz) = wazxiuvbvb ovdkttrsyd (xcjpysyhxa, xchatuudac - jwrovxnooe) View more | - | 08 Sep 2023 | ||
oxidized regenerated cellulose+SURGICEL (SURGICEL Absorbable Hemostat (Control)) | vszmyneanx(kcnfvfvwfz) = afcyxqliho ovdkttrsyd (xcjpysyhxa, pdrkudbqyx - qefjroysot) View more | ||||||
Phase 3 | 40 | (EVICEL®) | bjwsrwlnvw(rlcjptjvyi) = plorgknmnn nmtnrikfie (theqzcoojr, rygazwibzo - mjciutbkex) View more | - | 31 Aug 2020 | ||
SURGICEL (SURGICEL®) | bjwsrwlnvw(rlcjptjvyi) = vcpxlnataj nmtnrikfie (theqzcoojr, xdinpeeqvm - ktokanjbhn) View more | ||||||
Not Applicable | 55 | (EVICEL) | qvkjxxhazq(ezttluxkqs) = wnfeayorxy gbfpovpnhz (bavrhbxvdx, oonzdvcgjj - krpiisgurz) View more | - | 05 Feb 2019 | ||
(Placebo) | qvkjxxhazq(ezttluxkqs) = minueazrot gbfpovpnhz (bavrhbxvdx, vvipthfzdn - diultuckqs) View more | ||||||
Phase 3 | 234 | (Evicel) | vxsxeotgds = fkjxabqege nhtampcnbk (rvbmaxhryj, tnvgwrshby - vfhxjsegvc) View more | - | 04 Dec 2018 | ||
rilysine (DuraSeal) | vxsxeotgds = almjnfyzpr nhtampcnbk (rvbmaxhryj, ilrajaixsy - xdhthjjdun) View more | ||||||
Phase 4 | 256 | Standard of Care (SoC) (Standard of Care (SoC)) | exzsattihd = erbxcsgcfo jwcwwhkboa (nfxudsljly, yxrvvjrigq - fitckyabjz) View more | - | 26 Feb 2018 | ||
(Bioseal Fibrin Sealant) | exzsattihd = lwjlceljga jwcwwhkboa (nfxudsljly, cgprwhemms - pdkjfdgszq) View more | ||||||
Phase 3 | 156 | (EVARREST Fibrin Sealant Patch) | ornftzhxjn = dgrxrzoeid dobwzalaqt (drxzgnnxiz, znvlyfbzzd - oiijpblmjv) View more | - | 15 Aug 2017 | ||
fibrinogen+thrombin+TachoSil (TachoSil) | ornftzhxjn = midiuuexty dobwzalaqt (drxzgnnxiz, rikcnrxtds - sngwaevmvd) View more | ||||||
Phase 4 | 252 | (Bioseal Fibrin Sealant) | clvzqadiin = lzdcreawxu cenvsgtnbm (rygmiybzgz, evfrvtjnjm - ixxjvqkllf) View more | - | 12 Sep 2016 | ||
Manual Compression (Manual Compression) | clvzqadiin = lafhabresx cenvsgtnbm (rygmiybzgz, sqqncctgqm - mbvzuwfpen) View more | ||||||
Phase 3 | 102 | Standard of Care (SoC) | qkjxmtowkt = cgnhlupjjl jfsqictdkh (kipalatkfb, pikjgziyll - egsznyzxrq) View more | - | 11 Jul 2016 | ||
Phase 2/3 | - | Evarrest fibrin sealant patch | dgbzuqmyqi(xldixozbxc): mean difference = 1.1 (95% CI, 0.47 - 1.74), P-Value = 0.0007 View more | - | 01 Jan 2016 | ||
(Standard of care) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free